Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - INTERMUNE INC | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 23, 2010
INTERMUNE, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 0-29801 | 94-3296648 | |
| (Commission File Number) | (IRS Employer Identification Number) |
3280 Bayshore Boulevard
Brisbane, CA 94005
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (415) 466-2200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On March 23, 2010, InterMune, Inc., or the Company, announced that the European Medicines Agency, or the EMA, validated the Company’s Marketing Authorization Application, or the MAA, submitted on March 2, 2010, seeking approval of pirfenidone for the treatment of ideopathic pulmonary fibrosis, or IPF, in adults. Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24, 2010. If approved by the EMA, pirfenidone would be the first medication to be made available to IPF patients in the European Union.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit |
Description | |
| 99.1 | Press release dated March 23, 2010. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 23, 2010 | INTERMUNE, INC. | |||||
| By: | /s/ JOHN C. HODGMAN | |||||
| John C. Hodgman | ||||||
| Senior Vice President of Finance Administration and Chief Financial Officer | ||||||
EXHIBIT INDEX
| Exhibit |
Description | |
| 99.1 | Press release dated March 23, 2010. | |